US medical devices industry saw a drop of 10.98% in overall deal activity during February 2021, when compared with the last 12-month average, led by Veracyte ’s $600m acquisition of Decipher Biosciences , according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 73 deals worth $1.73bn were announced in February 2021, compared with the 12-month average of 82 deals.

venture financing was the leading category in the month in terms of volume with 40 deals, which accounted for 54.8% of all deals.

In second place was M&A with 28 deals, followed by private equity with five transactions, respectively accounting for 38.4% and 6.9% of overall deal activity in the US technology industry during the month.

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $831.84m, while venture financing and private equity deals totalled $811.82m and $84.87m respectively.

US medical devices industry deals in February 2021: Top deals

The top five medical devices industry deals accounted for 60.6% of the overall value during February 2021.

The combined value of the top five medical devices deals stood at $1.05bn, against the overall value of $1.73bn recorded for the month.

The top five medical devices industry deals of February 2021 tracked by GlobalData were:

1) Veracyte’s $600m acquisition of Decipher Biosciences

2) The $150m acquisition of Simplify Medical by NuVasive

3) DNS Capital , General Catalyst Partners , Glen Tullman , GreatPoint Ventures , TYH Ventures , Wasson Enterprise and Wittington Ventures ‘ $105m venture financing of Truvian Sciences

4) The $103m venture financing deal with Personal Genome Diagnostics by Catalio Capital Management , Cowen Healthcare Investments , Innovatus Capital Partners , Kern Capital Management , New Enterprise Associates , Northpond Ventures , PFM Health Sciences , Rock Springs Capital Management , Sands Capital Management , Vensana Capital and Windham Venture Partners

5) Altium Capital , Axiom Associates , Colle Capital Partners , GV Management Co, Huamin Investment Management and Nextrans ‘ venture financing with Hyperfine Research for $90m.